KELLI CASH: Open Payments
NPI 1023595154 · STAUNTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,782 in 242 payments from 18 companies in 2025. Trend: 2023 $2,723 · 2024 $3,038 · 2025 $3,782
Food & beverage: $3,782
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $646 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 52 | $476 |
| Vanda Pharmaceuticals Inc. | 19 | $418 |
| Otsuka America Pharmaceutical, Inc. | 32 | $403 |
| Janssen Pharmaceuticals, Inc | 15 | $378 |
| Alkermes, Inc. | 25 | $373 |
| E.R. Squibb & Sons, L.L.C. | 11 | $307 |
| Lundbeck LLC | 23 | $276 |
| Neurocrine BioSciences, Inc. | 12 | $233 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
Products named: VRAYLAR, CAPLYTA, REXULTI, COBENFY, INVEGA SUSTENNA, ARISTADA, FANAPT, INGREZZA.
Industry payments across VA — which companies pay providers there.
